Multiple Sclerosis Lecture Series: Novel Therapies

Thursday, September 4, 2025, 12:00 AM - Tuesday, September 5, 2028, 11:59 PM, On Demand

Presented by the Stanford University School of Medicine Department of Neurology and Center for Continuing Medical Education.

What are the new innovative treatment strategies indicated for the treatment of MS? Watch the fifth and final lecture in the MS Series to learn about the novel therapies that are at the precipice of transforming the field in patient care. In this talk, Dr. Lucas Kipp explores the mechanisms of progressive MS, remyelination, and Epstein Barr Virus treatments.

  Original Release Date: September 6, 2022

  Review Date: June 11, 2025

  Expiration Date: September 05, 2028

  Estimated Time To Complete: 39 minutes

  Registration Fee: FREE

Click Begin tab to launch the course. View the entire Multiple Sclerosis Series here.

AMA PRA Category 1 Credits™ (0.75 hours), Non-Physician Participation Credit (0.75 hours)

1. Recognize the unmet needs in effectively treating MS.
2. Summarize the proposed mechanisms of progressive MS.
3. Recall novel therapies that aim to address treatment gaps.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, please contact the Coordinator.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography

·       Alotaibi, Suad, Julia Kennedy, Raymond Tellier, Derek Stephens, and Brenda Banwell. “Epstein-Barr Virus in Pediatric Multiple Sclerosis.” JAMA 291, no. 15 (April 21, 2004): 1875–79. https://doi.org/10.1001/jama.291.15.1875.
·       Ascherio, Alberto, and Kassandra L. Munger. “EBV and Autoimmunity.” In Epstein Barr Virus Volume 1: One Herpes Virus: Many Diseases, edited by Christian Münz, 365–85. Cham: Springer International Publishing, 2015. https://doi.org/10.1007/978-3-319-22822-8_15.
·       Atara Biotherapeutics. “A Phase 1/2, Two-Part, Open-Label Dose-Escalation and Double-Blind, Placebo-Controlled Dose-Expansion Study With an Open-Label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis.” Clinical trial registration. clinicaltrials.gov, July 21, 2022. https://clinicaltrials.gov/ct2/show/NCT03283826.
·       Bajracharya, Rinie, Alayna C. Caruso, Laura J. Vella, and Rebecca M. Nisbet. “Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain.” Pharmaceutics 13, no. 12 (2021). https://doi.org/10.3390/pharmaceutics13122014.
·       Biogen. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies.” Clinical trial registration. clinicaltrials.gov, April 1, 2022. https://clinicaltrials.gov/ct2/show/NCT03222973.
·       Bjornevik, Kjetil, Marianna Cortese, Brian C. Healy, Jens Kuhle, Michael J. Mina, Yumei Leng, Stephen J. Elledge, et al. “Longitudinal Analysis Reveals High Prevalence of Epstein-Barr Virus Associated with Multiple Sclerosis.” Science 375, no. 6578 (January 21, 2022): 296–301. https://doi.org/10.1126/science.abj8222.
·       Cadavid, Diego, Laura Balcer, Steven Galetta, Orhan Aktas, Tjalf Ziemssen, Ludo Vanopdenbosch, Jette Frederiksen, et al. “Safety and Efficacy of Opicinumab in Acute Optic Neuritis (RENEW): A Randomised, Placebo-Controlled, Phase 2 Trial.” The Lancet. Neurology 16, no. 3 (March 2017): 189–99. https://doi.org/10.1016/S1474-4422(16)30377-5.
·       Cadavid, Diego, Michelle Mellion, Raymond Hupperts, Keith R. Edwards, Peter A. Calabresi, Jelena Drulovic, Gavin Giovannoni, et al. “Safety and Efficacy of Opicinumab in Patients with Relapsing Multiple Sclerosis (SYNERGY): A Randomised, Placebo-Controlled, Phase 2 Trial.” The Lancet Neurology 18, no. 9 (September 1, 2019): 845–56. https://doi.org/10.1016/S1474-4422(19)30137-1.
·       Calvi, Alberto, Lukas Haider, Ferran Prados, Carmen Tur, Declan Chard, and Frederik Barkhof. “In Vivo Imaging of Chronic Active Lesions in Multiple Sclerosis.” Multiple Sclerosis (Houndmills, Basingstoke, England) 28, no. 5 (April 2022): 683–90. https://doi.org/10.1177/1352458520958589.
·       Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts. “Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis.” Clinical trial registration. clinicaltrials.gov, August 23, 2019. https://clinicaltrials.gov/ct2/show/NCT04042363.
·       Cui, Xinle, and Clifford M. Snapper. “Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.” Frontiers in Immunology 12 (2021). https://www.frontiersin.org/articles/10.3389/fimmu.2021.734471.
·       Dolgin, Elie. “BTK Blockers Make Headway in Multiple Sclerosis.” Nature Biotechnology 39, no. 1 (January 1, 2021): 3–5. https://doi.org/10.1038/s41587-020-00790-7.
·       Duffy, Conor P., and Claire E. McCoy. “The Role of MicroRNAs in Repair Processes in Multiple Sclerosis.” Cells 9, no. 7 (2020). https://doi.org/10.3390/cells9071711.
·       Eisele, Philipp, Katja Fischer, Kristina Szabo, Michael Platten, and Achim Gass. “Characterization of Contrast-Enhancing and Non-Contrast-Enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging.” Frontiers in Neurology 10 (2019). https://www.frontiersin.org/articles/10.3389/fneur.2019.01082.
·       Filippi, Massimo, Wolfgang Brück, Declan Chard, Franz Fazekas, Jeroen J. G. Geurts, Christian Enzinger, Simon Hametner, et al. “Association between Pathological and MRI Findings in Multiple Sclerosis.” The Lancet Neurology 18, no. 2 (February 1, 2019): 198–210. https://doi.org/10.1016/S1474-4422(18)30451-4.
·       Fox, Robert J., Christopher S. Coffey, Robin Conwit, Merit E. Cudkowicz, Trevis Gleason, Andrew Goodman, Eric C. Klawiter, et al. “Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.” New England Journal of Medicine 379, no. 9 (August 30, 2018): 846–55. https://doi.org/10.1056/NEJMoa1803583.
·       Francisco, San. EYETRONIC® - Restoring Vision in Glaucoma. n.d.
·       Franklin, Robin J. M., and Charles ffrench-Constant. “Regenerating CNS Myelin — from Mechanisms to Experimental Medicines.” Nature Reviews Neuroscience 18, no. 12 (December 1, 2017): 753–69. https://doi.org/10.1038/nrn.2017.136.
·       García-Merino, Antonio. “Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.” Cells 10, no. 10 (September 27, 2021). https://doi.org/10.3390/cells10102560.
·       “Genentech: Our Pipeline.” Accessed August 31, 2022. https://www.gene.com/medical-professionals/pipeline?phase=1&category=neuroscience.
·       Green, Ari J., Jeffrey M. Gelfand, Bruce A. Cree, Carolyn Bevan, W. John Boscardin, Feng Mei, Justin Inman, et al. “Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial.” The Lancet 390, no. 10111 (December 2, 2017): 2481–89. https://doi.org/10.1016/S0140-6736(17)32346-2.
·       Handel, Adam E., Alexander J. Williamson, Giulio Disanto, Lahiru Handunnetthi, Gavin Giovannoni, and Sreeram V. Ramagopalan. “An Updated Meta-Analysis of Risk of Multiple Sclerosis Following Infectious Mononucleosis.” PLOS ONE 5, no. 9 (September 1, 2010): e12496. https://doi.org/10.1371/journal.pone.0012496.
·       Howell, Owain W., Cheryl A. Reeves, Richard Nicholas, Daniele Carassiti, Bishan Radotra, Steve M. Gentleman, Barbara Serafini, et al. “Meningeal Inflammation Is Widespread and Linked to Cortical Pathology in Multiple Sclerosis.” Brain 134, no. 9 (September 1, 2011): 2755–71. https://doi.org/10.1093/brain/awr182.
·       Ineichen, Benjamin V., Charidimos Tsagkas, Martina Absinta, and Daniel S. Reich. “Leptomeningeal Enhancement in Multiple Sclerosis and Other Neurological Diseases: A Systematic Review and Meta-Analysis.” NeuroImage. Clinical 33 (2022): 102939. https://doi.org/10.1016/j.nicl.2022.102939.
·       Karussis, Dimitrios. “Modern MS Management: The Present and the Future.” Rishon LeZion, 2019. https://cdn.mednet.co.il/2019/05/1420-kanussis-hall1-tue.pdf.
·       Kilsdonk, Iris D., Laura E. Jonkman, Roel Klaver, Susanne J. van Veluw, Jaco J. M. Zwanenburg, Joost P. A. Kuijer, Petra J. W. Pouwels, et al. “Increased Cortical Grey Matter Lesion Detection in Multiple Sclerosis with 7 T MRI: A Post-Mortem Verification Study.” Brain 139, no. 5 (May 1, 2016): 1472–81. https://doi.org/10.1093/brain/aww037.
·       Krieger, Stephen C., Karin Cook, Scott De Nino, and Madhuri Fletcher. “The Topographical Model of Multiple Sclerosis.” Neurology - Neuroimmunology Neuroinflammation 3, no. 5 (October 1, 2016): e279. https://doi.org/10.1212/NXI.0000000000000279.
·       Lanz, Tobias V., R. Camille Brewer, Peggy P. Ho, Jae-Seung Moon, Kevin M. Jude, Daniel Fernandez, Ricardo A. Fernandes, et al. “Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.” Nature 603, no. 7900 (March 2022): 321–27. https://doi.org/10.1038/s41586-022-04432-7.
·       Lassmann, Hans. “Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.” Frontiers in Immunology 9 (2019). https://www.frontiersin.org/articles/10.3389/fimmu.2018.03116.
·       Levin, Lynn I., Kassandra L. Munger, Eilis J. O’Reilly, Kerstin I. Falk, and Alberto Ascherio. “Primary Infection with the Epstein-Barr Virus and Risk of Multiple Sclerosis.” Annals of Neurology 67, no. 6 (2010): 824–30. https://doi.org/10.1002/ana.21978.
·       Lubetzki, Catherine, Bernard Zalc, Anna Williams, Christine Stadelmann, and Bruno Stankoff. “Remyelination in Multiple Sclerosis: From Basic Science to Clinical Translation.” The Lancet Neurology 19, no. 8 (August 1, 2020): 678–88. https://doi.org/10.1016/S1474-4422(20)30140-X.
·       Moderna. “EBV Vaccines (MRNA-1189 & MRNA-1195).” PDF, n.d. https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2022/08/EBV-(08-03-22).pdf.
·       Munger, KL, LI Levin, EJ O’Reilly, KI Falk, and A Ascherio. “Anti-Epstein–Barr Virus Antibodies as Serological Markers of Multiple Sclerosis: A Prospective Study among United States Military Personnel.” Multiple Sclerosis Journal 17, no. 10 (October 1, 2011): 1185–93. https://doi.org/10.1177/1352458511408991.
·       Nelson, F., A. H. Poonawalla, P. Hou, F. Huang, J. S. Wolinsky, and P. A. Narayana. “Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging.” American Journal of Neuroradiology 28, no. 9 (October 1, 2007): 1645–49. https://doi.org/10.3174/ajnr.A0645.
·       “Neurobiology of Brain Disorders - 1st Edition.” Accessed August 30, 2022. https://www.elsevier.com/books/neurobiology-of-brain-disorders/zigmond/978-0-12-398270-4.
·       Ontaneda, Daniel. “Progressive Multiple Sclerosis.” Continuum (Minneapolis, Minn.) 25, no. 3 (June 2019): 736–52. https://doi.org/10.1212/CON.0000000000000727.
·       Pender, M. P., S. J. Hodgkinson, S. Broadley, J. W. Lindsey, Z. A. Ioannides, B. Bagert, L. Gamelin, et al. “Updated Open-Label Extension Clinical Data and New Magnetization Transfer Ratio Imaging Data from a Phase I Study of ATA188, an off-the-Shelf, Allogeneic Epstein-Barr Virus-Targeted T-Cell Immunotherapy for Progressive Multiple Sclerosis,” 27:552–53. Sage Publications Ltd, 2021. https://research-repository.griffith.edu.au/handle/10072/414091.
·       Pender, Michael P, Suzanne Hodgkinson, Simon Broadley, John W Lindsey, Zara A Ioannides, Bridget Bagert, Rajiv Khanna, et al. “Phase I Study of ATA188, an off-the-Shelf, Allogeneic Epstein-Barr Virus-Targeted T-Cell Immunotherapy for Progressive Forms of Multiple Sclerosis,” n.d.
·       Preziosa, Paolo, Elisabetta Pagani, Alessandro Meani, Lucia Moiola, Mariaemma Rodegher, Massimo Filippi, and Maria A. Rocca. “Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.” Neurology - Neuroimmunology Neuroinflammation 9, no. 2 (March 1, 2022): e1139. https://doi.org/10.1212/NXI.0000000000001139.
·       National Multiple Sclerosis Society. “Research.” Accessed August 30, 2022. https://www.nationalmssociety.org/Research.
·       Scalfari, Antonio, Anneke Neuhaus, Martin Daumer, Paolo Antonio Muraro, and George Cornell Ebers. “Onset of Secondary Progressive Phase and Long-Term Evolution of Multiple Sclerosis.” Journal of Neurology, Neurosurgery & Psychiatry 85, no. 1 (January 1, 2014): 67. https://doi.org/10.1136/jnnp-2012-304333.
·       Sun, Cong, Xin-chun Chen, Yin-feng Kang, and Mu-sheng Zeng. “The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development.” Frontiers in Immunology 12 (2021). https://www.frontiersin.org/articles/10.3389/fimmu.2021.677027.
·       Sundqvist, E., P. Sundström, M. Lindén, A K Hedström, F. Aloisi, J. Hillert, I. Kockum, L. Alfredsson, and T. Olsson. “Epstein-Barr Virus and Multiple Sclerosis: Interaction with HLA.” Genes & Immunity 13, no. 1 (January 1, 2012): 14–20. https://doi.org/10.1038/gene.2011.42.
·       Torke, Sebastian, and Martin S. Weber. “Inhibition of Bruton´s Tyrosine Kinase as a Novel Therapeutic Approach in Multiple Sclerosis.” Expert Opinion on Investigational Drugs 29, no. 10 (October 2, 2020): 1143–50. https://doi.org/10.1080/13543784.2020.1807934.
·       Drugs.com. “Wal Hist (Tablet) Walgreen Company.” Accessed August 31, 2022. https://www.drugs.com/otc/116926/wal-hist.html.

·     Kohrt, BA, Ojagbemi, A, Luitel, NP, et al. (n.d.). An App-Based WHO Mental Health Guide for Depression Detection: A Cluster Randomized Clinical Trial.. JAMA network open. https://pubmed.ncbi.nlm.nih.gov/40408108

·     Zuelsdorff, M, Abner, EL, Balls-Berry, JE, et al. (n.d.). Introducing social determinants of health to the Alzheimer's Disease Research Center network: Development and implementation in the Uniform Data Set.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://pubmed.ncbi.nlm.nih.gov/40407095

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

This educational activity is supported in part by an educational grant from Novartis Pharmaceuticals Corporation.